Medullary thyroid carcinoma and calcitonin

Area of Science:

• Endocrinology
• Oncology
• Biochemistry

Background:

• Medullary carcinoma of the thyroid (MCT) originates from thyroid C-cells, which secrete calcitonin (CT).
• Elevated serum calcitonin levels are characteristic of MCT, with higher molecular weight substances also contributing to immunoreactivity.
• The physiological regulation of CT secretion and its role in bone metabolism are areas of ongoing research.

Purpose of the Study:

• To describe a sensitive radioimmunoassay for measuring serum calcitonin (CT) and immunoreactive CT (iCT).
• To investigate the relationship between serum iCT levels and medullary thyroid carcinoma (MCT).
• To explore the effects of CT on bone remodeling and vitamin D metabolism in MCT patients.

Main Methods:

• Development and application of a direct sequential radioimmunoassay for human serum calcitonin (CT).
• Measurement of serum iCT levels in healthy subjects and patients with MCT.
• Provocative testing using pentagastrin and/or calcium to assess CT secretion.
• Analysis of serum 1,25-dihydroxyvitamin D and bone remodeling markers in MCT patients.

Main Results:

• A sensitive radioimmunoassay for serum iCT was established, detecting elevated levels in most MCT patients.
• Serum iCT levels showed minimal diurnal variation and were often elevated even in clinically occult MCT.
• MCT patients exhibited increased serum 1,25-dihydroxyvitamin D and bone remodeling, which normalized after surgical treatment.

Conclusions:

• Elevated serum iCT is a reliable marker for medullary thyroid carcinoma (MCT), with provocative testing aiding early detection.
• Chronic CT excess in MCT may enhance 1,25-dihydroxyvitamin D production, influencing bone remodeling.
• Calcitonin's physiological role may involve bone preservation during increased calcium demand, with deficiency potentially linked to osteoporosis.